EUVIMEDEUVIMED entdecken
Übersichtsarbeit

New developments in the diagnosis and management of motor neuron disease

David O'Brien, Pamela J Shaw iD

British Medical Bulletin · 12.12.2024 · 152 (1) · 4-15

DOI: 10.1093/bmb/ldae010 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Medical Bulletin, online erschienen am 29.09.2024. Verfasst von David O'Brien und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 285 Glossop Road, Sheffield S10 2HQ, United Kingdom. Hauptthemen laut MEDLINE: Motor Neuron Disease. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: NIHR Sheffield Biomedical Research Centre, AMBRoSIA Biosampling Programme, MNDA (Sheffield Care and Research Centre for Motor Neuron Disorders.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction Motor neuron disease (MND) is a devastating neurodegenerative disease characterized by progressive muscle weakness. Sources of data PubMed, MEDLINE, and Cochrane databases were searched for articles to March 2024. Searches involved the terms ‘motor neuron disease’ or ‘amyotrophic lateral sclerosis’ and ‘epidemiology’, ‘diagnosis’, ‘clinical’, ‘genetic’, ‘management’, ‘treatment’, or ‘trial’. Areas of agreement Evidence-based management involves riluzole, multidisciplinary care, provision of noninvasive ventilation and gastrostomy, and symptomatic treatments. Tofersen should be offered to treat SOD1-MND. Areas of controversy Edaravone and Relyvrio are approved treatments in the USA, but insufficient evidence was found to support approval in the UK and Europe. Growing points The discovery of neurofilaments as MND biomarkers, growth of platform trials and development of novel therapies provide optimism for more powerful neuroprotective therapies. Areas timely for developing research Further work should focus on the elucidation of environmental causes of MND, gene–environment interactions, and advanced cellular models of disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Motor Neuron DiseaseHumansNeuroprotective AgentsRiluzole

Stichwörter der Autor:innen

diagnosismanagementmotor neuron disease

Substanzen

Neuroprotective AgentsRiluzole

Autor:innen und Institutionen

  • Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, 285 Glossop Road, Sheffield S10 2HQ, United Kingdom.

ORCID-Profile: Pamela J Shaw

Förderung

  • NIHR Sheffield Biomedical Research Centre
  • AMBRoSIA Biosampling Programme
  • MNDA (Sheffield Care and Research Centre for Motor Neuron Disorders

Zitieren

APA

O'Brien, D., & Shaw, P. J. (2024). New developments in the diagnosis and management of motor neuron disease. British Medical Bulletin, 152(1), 4-15. https://doi.org/10.1093/bmb/ldae010

Vancouver

O'Brien D, Shaw PJ. New developments in the diagnosis and management of motor neuron disease. British Medical Bulletin. 2024;152(1):4-15. doi:10.1093/bmb/ldae010

BibTeX
@article{OBrien2024,
  author = {O'Brien, David and Shaw, Pamela J},
  title = {New developments in the diagnosis and management of motor neuron disease},
  journal = {British Medical Bulletin},
  year = {2024},
  volume = {152},
  number = {1},
  pages = {4--15},
  doi = {10.1093/bmb/ldae010}
}
Kostenlos starten →